Integrative computational approach identifies drug targets in CD4⁺ T-cell-mediated immune disorders

Area of Science:

• Immunology
• Systems Biology
• Metabolic Engineering

Background:

• CD4+ T cells are crucial for adaptive immunity but implicated in autoimmune diseases.
• Metabolic dysregulation in CD4+ T cells presents a therapeutic target for immune-related pathologies.
• Genome-scale metabolic modeling accelerates drug discovery by defining targetable metabolic pathways.

Purpose of the Study:

• To develop genome-scale metabolic models for distinct CD4+ T-cell subtypes (naïve, Th1, Th2, Th17).
• To map metabolic perturbations in rheumatoid arthritis, multiple sclerosis, and primary biliary cholangitis.
• To identify potential drug targets for these autoimmune diseases through in silico simulations and experimental validation.

Main Methods:

• Construction of genome-scale metabolic models for four CD4+ T-cell subtypes.
• In silico drug response analysis using FDA-approved drugs and compounds.
• Integration of disease-specific gene expression data with metabolic models to identify drug targets.
• In vitro validation of identified drug targets.

Main Results:

• Developed metabolic models for naïve, Th1, Th2, and Th17 CD4+ T-cell subtypes.
• Identified 68 potential drug targets for rheumatoid arthritis, multiple sclerosis, and primary biliary cholangitis.
• Experimental validation confirmed that modulating 50% of these targets suppressed CD4+ T-cell activity.

Conclusions:

• Genome-scale metabolic modeling is effective for identifying therapeutic targets in autoimmune diseases.
• The validated drug targets offer promising avenues for developing novel immunomodulatory therapies.
• The developed metabolic models provide a platform for further research into CD4+ T-cell metabolism and disease mechanisms.